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Background: Hyaluronan is a critical component of extracellular matrix with several different roles. Besides the
contribution to the tissue hydration,mechanical properties and correct architecture, hyaluronan plays important
biological functions interacting with different molecules and receptors.
Scope of review: The review addresses the control of hyaluronan synthesis highlighting the critical role of
hyaluronan synthase 2 in this context as well as discussing the recent ﬁndings related to covalent modiﬁcations
which inﬂuence the enzyme activity. Moreover, the interactions with speciﬁc receptors and hyaluronan are de-
scribed focusing on the importance of polymer size in the modulation of hyaluronan signaling.
Major conclusions: Due to its biological effects on cells recently described, it is evident how hyaluronan is to be
considered not only a passive component of extracellular matrix but also an actor involved in several scenarios
of cell behavior.
General signiﬁcance: The effects of metabolism on the control of hyaluronan synthesis both in healthy and path-
ologic conditions are critical and still not completely understood. The hyaluronan capacity to bind several recep-
tors triggering speciﬁc pathwaysmay represent a valid target for new approach in several therapeutic strategies.
This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Extracellularmatrix (ECM) is a complex network ofmacromolecules
that surrounds cells not only to mechanically support cells and tissue
structure, but also to control nutrient and waste exchanges, cell–cell
and cell–matrix interactions, and signaling molecular diffusion. Thus,
ECM is critical to regulate cell behavior and increasing bodyof evidences
supports the ECM involvement in both physiological as well as patholog-
ical processes. The cell microenvironment has a pivotal role in several
pathologies as tumors and cardiovascular diseases, in which alterations
of cell functions can be exacerbated by external stimuli and altered ECM
composition [1–4].
Glycosaminoglycans (GAGs) differ from the other ECM components
as they are complex polysaccharides which can carry many chemical
possible modiﬁcations (i.e., sulfation, acetylation and epimerization)
and are covalently linked to a core protein forming proteoglycans
(PGs). Such variability permits to these macromolecules to ﬁnely
modulate protein–protein interactions, enzymatic activity or diffusion
of signalling molecules.
Hyaluronan is an atypical and relatively simple GAG, in fact it
is an unsulfated and unbranched polysaccharide not linked to
any PG core proteins. Hyaluronan is ubiquitously expressed
in the ECM of mammals and is composed D-glucuronic acid-mediated cell behaviour and
39 0332 397119.
ights reserved.(GlcUA) and N-acetyl-D-glucosamine (GlcNAc) bound together through
β1,3 and β1,4 glycosidic bonds, respectively [5]. This disaccharidemoiety
is repeated thousands of times generating a linear polymerwith amolec-
ular mass ranging from 5 × 105 to 4–5 × 106 Da and more. Due to its hy-
drophilic properties, hyaluronan is very hydrated causing the ECM an
ideal environment in which cells can move and proliferate. Hyaluronan
is an important space ﬁlling molecule as it is evident in humor vitreous,
derma and at joint level. Besides its molecular sieving properties related
to the chemical and bio-mechanical characteristics of hyaluronan, this
polymer interacting with speciﬁc proteins called hyaladerins, such as
TSG6, andmembrane receptors like CD44, RHAMM,HARE and toll like re-
ceptor (TLR) 4/2, modulates the development, the morphogenesis, the
tumorigenesis, the migration, the apoptosis, the cell survival and the in-
ﬂammation [6–9]. This review focuses on hyaluronan biosynthesis regu-
lation and signaling. On these bases the knowledge of how hyaluronan
is produced by the cells and how its metabolism is regulated is of great
interest. Growing mass of data related to the control of hyaluronan syn-
thesis is reported in literature in various models and pathologies, and
these aspects will be discussed in this work.
2. Hyaluronan synthesis regulation
Although the relatively simple structure, hyaluronan possesses
many physiological roles. Surprisingly, hyaluronan appeared late during
evolution and can be typically found from chordates. Interestingly,
some pathogenic bacteria acquired the capability of synthesize
hyaluronan that use as a mimetic shield against the host immune sys-
tem. How bacteria acquired the ability to synthesize hyaluronan is still
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duce hyaluronan capsule. Interestingly these three genes, which encode
UDP-Glucose pyrophosphorylase (hasC), UDP-Glucose dehydrogenase
(hasB) and hyaluronan synthase (hasA), are located in an operon, sug-
gesting the critical role of precursors in hyaluronan biosynthesis
[10–12].
In mammals, hyaluronan synthesis occurs on the cellular plasma
membrane (contrary to the other GAG synthesis that is in the Golgi ap-
paratus) by means of three hyaluronan synthase isoenzymes (HAS1, 2,
and 3) that utilize the uridine diphosphate (UDP) glucuronic acid
(UDP-GlcUA) and UDP N-acetylglucosamine (UDP-GlcNAc) as sub-
strates. These two sugar nucleotides have critical functions to regulate
hyaluronan synthesis through the modulation of gene expression
of HASes and by altering HAS enzymatic activity and stability. UDP-
Glucose pyrophosphorylase and UDP-Glucose dehydrogenase medi-
ating the synthesis of UDP-glucose and UDP-GlcUA, respectively,
have a positive effect on hyaluronan synthesis increasing the avail-
ability of one of the HAS substrate [13,14]. Whether or not the activity
of HAS enzymes during the sorting to the plasma membrane is still
unclear, but it seems that these proteins could be functional in endo-
plasmic reticulum and Golgi [15]. Interestingly, UDP-GlcUA is able to
inﬂuence the accumulation of HAS2 and 3 transcripts, although the
molecular mechanism of such regulation is still not known.
The physiological role of HAS isoenzymes is not yet understood;
in vitro HASes have different biochemical properties in terms of size of
hyaluronan synthesized and catalytic efﬁciency [16]. Hyaluronan chain
size is critical in many pathophysiological conditions [17,18]. Due to
the action of hyaluronidases [19] or the action of oxygen radicals [20],
hyaluronan can be fragmented in short oligosaccharides that can trigger
inﬂammation ormetalloproteinase activation [21,22]. Alternatively, low
molecular weight hyaluronan could be produced by HAS3 [23]. Other
mechanisms to alter hyaluronan synthesis can directly involve HAS en-
zymes by, for instance, post-translational modiﬁcations or by alteration
of the UDP-sugar pool as already discussed [24,25].
Increased hyaluronan levels are often described in the presence of
elevated activities of growth factors and cytokines that are released in
rapidly remodeling tissues as during embryonic development and
would healing or during certain pathological situations, such as inﬂam-
mation, tumor progression, and vessel thickening.
Smooth muscle cells (SMCs) have a critical role in cardiovascular
pathologies as they strongly contribute to neointima formation.
Hyaluronan has pro-atherosclerotic properties controlling SMC pro-
liferation, migration and contributing to immune cell recruitment.
Several experiments conﬁrmed this effect by using CD44 knockout ani-
mals [26], HAS2 transgenic mice [27], by blocking HA/CD44 interaction
or inhibiting hyaluronan synthesis. On these bases, many efforts have
been done to study the regulation of hyaluronan synthesis in SMCs.
From these studies it is now clear that HAS2, themost abundant and ac-
tive HAS isoenzymes, has several levels of regulation to coordinate
hyaluronan production with the cellular metabolism [28].
Although HASes do not use directly ATP, the synthesis of UDP-GlcUA
and UDP-GlcNAc precursors requires ATP, UTP and other critical meta-
bolic molecules as glucose, glutamine, glucosamine and acetyl-CoA, in
order to perform the GAG production, an energy consuming process. It
is well known that energy charge of the cell has a central role in the
integration of the entire metabolism. Although, many enzymes can di-
rectly use ATP, ADP and AMP as allosteric modulators, the adenosine
monophosphate activated protein kinase (AMPK) has a pivotal role as
metabolic sensor and regulator. AMPK is a heterotrimeric protein
formed by catalytic α subunit and two regulatory subunits. When the
ATP:AMP ratio is high, AMPK is not active, but, when ATP:AMP ratio
decreases, the catalytic subunit can be phosphorylated by AMPK up-
stream kinases triggering AMPK activation. In this active form, AMPK
is able to phosphorylate several target proteins that lead to the inhibi-
tion of anabolic processes and, in the same time, increasing catabolic
pathways with the results to restore ATP levels [29]. AMPK speciﬁcallyinhibited hyaluronan synthesis without altering other GAGs in
human SMC and in mouse embryonic ﬁbroblasts [30]. The reduction
of hyaluronan accumulationmediated a decrement of SMC proliferation
and migration highlighting as the blocking of hyaluronan can be a new
candidate to develop vasoprotective drugs. From a molecular point of
view, AMPK phosphorylates HAS2 at threonine 110 (T110); this residue
is located on a cytosolic loop of the enzymewhich is known to be critical
for the enzymatic activity. Interestingly, the action of AMPK could be
more complex and tissue speciﬁc as in human dermal ﬁbroblasts the
activation of AMPK induces HAS2 messenger accumulation [31].
HAS2 can also undergo to the regulation by O-GlcNAcylation.
This latter is an intracellular glycosylation mediated by O-GlcNac
transferase (OGT) which catalyzes the β-O-linkage of one residue of
N-acetylglucosamine (GlcNAc) to serine or threonine of proteins [32].
The donor of GlcNAc is UDP-GlcNAc, which is synthesized by the
hexosamine biosynthetic pathway (HBP) (Fig. 1). HBP is now consid-
ered one of the main nutrient sensor as, not only is able to directly
recognize the availability of glucose (the more glucose, the more ﬂux
though the HBP), but the synthesis of UDP-GlcNAc depends on the me-
tabolism of fatty acids, amino acids, and nucleotides. The pathological
relevance of HBP is well known in diabetes, in fact the hyperglycemic
condition leads to an increase of UDP-GlcNAc that, in turn, leads to an
increase of O-GlcNAcylation [33]. High blood glucose is the cause of di-
abetic complications (i.e., angiopathies, neuropathies, nephropathies,
and retinopathies) which can dramatically affect the patient's lifestyle.
However, which molecular mechanisms modiﬁed by the excess of
glucose are still debated, but O-GlcNAcylation seems to have a central
role. Hyaluronan accumulates in the aortas of diabetic subjects [34]
and in hyperglycemic animal models hyaluronan increased in vessels
[35]. HAS2 can be modiﬁed by O-GlcNAc at serine 221 (S221) and
such glycosylation induced a great stability of the enzyme in cellular
plasma membrane inducing an enhanced hyaluronan synthesis [36].
HAS2 is rapidly degraded by the 26S proteasome and O-GlcNAcylation
preventedHAS2 degradation. Themolecularmechanismof such protec-
tion against proteasomal digestion is not understood although it is
known that O-GlcNAcylation can directly affect proteasomal activity
and ubiquitination. Interestingly, HAS2 can form dimers or oligomers
and is subjected to regulatory ubiquitination i.e. is mono-ubiquitinated
at lysine residue 190 (K190) which has a key role for its activity and
dimerization [37] (Fig. 2A).
HAS2 represents the main hyaluronan synthetic enzyme in adult
cells and is reasonable that its activity is ﬁnely regulated. On the other
hand, HAS1 and HAS3 seem to have peculiar roles even if not complete-
ly clariﬁed. HAS1 seems to be important in hyperglycemic conditions
having a low afﬁnity for hyaluronan precursors, whereas HAS3 is
involved in the formation of particular microvilli structures [38,39].
Although HAS3 has been described to be phosphorylable when over
expressed in cells, the effects of AMPK and O-GlcNAcylation are speciﬁc
for HAS2 [30,36]. Interestingly, ERK increased the activity of all the three
HASes indicating that protein phosphorylation in residues different
from that modiﬁed by AMPK, can lead to hyaluronan accumulation
[40]. The regulation of HASes is also at transcriptional level, as previously
reviewed [41] and, recently, HAS2 and 3 have been demonstrated to be
similarly upregulated by oxidized LDL and 22-oxysterol which is the ag-
onist of Liver X Receptor agonist [42]. Although not deeply investigated
in mammals, bacterial HASes need a particular lipid microenvironment
(i.e., cardiolipin) [43] and, thus, eukaryotic HASes could have another
point of regulation through lipid metabolism and/or the presence of
lipid rafts.
Interestingly, the genomic locus of HAS2 can generate a natural
antisense transcript (NAT) of HAS2, named HAS2-AS1 and exon 2 of
HAS2-AS1 NAT is complemental to exon 1 of HAS2 mRNA. Although
several years ago HAS2-AS1 was described that the overexpression of
HAS2-AS1 decreased HAS2 mRNA [44], recently it has been described
that HAS2-AS1–HAS2 duplex at RNA level stabilized HAS2 messenger
leading to HAS2 accumulation [45] (Fig. 2B).
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Fig. 1. Schematic representation of the intracellular biochemical pathway for the biosynthesis of UDP-GlcUA and UDP-GlcNAc through the hexosamine biosynthetic pathway. G6P, glucose
6 phosphate; G1P, glucose 1 phosphate; UDP-G, UDP glucose, UDP-GlcUA, UDP-glucuronic acid; F6P, fructose 6 phosphate, GlcNAc6P, N-acetyl-glucosamine 6 phosphate; GlcNAc1P,
N-acetyl-glucosamine 1 phosphate; UDP-GlcNAc, UDP-N-acetyl-glucosamine. GLN, glutamine; GLU glutamate; Ac-CoA, acetyl-coenzyme A; PP, pyrophosphate. Reactions 1 and
2 are catalyzed by UDP-Glucose pyrophosphorylase and UDP-Glucose dehydrogenase, respectively.
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Despite its simple structure, hyaluronan has several interacting
properties with numerous proteins including matrix components and
cell membrane receptors (Fig. 3). It was reported that hyaluronan can
strongly interact with leukocytes throughout receptor CD44 contribut-
ing to the retention of these cells in inﬂammation site [46,47]. The
hyaluronan capacity to interact with cell receptors triggers several cell
responses that are speciﬁc for the cell types demonstrating that
this polymer possesses a strong capacity to modulate cell behaviorHAS2
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Fig. 2. A. Schematic representation of the covalent modiﬁcations on HAS2 protein which
modulate enzymatic activity. T, Threonine; K, lysine; S, serine; P, phosphate group; Ub,
mono-ubiquitination; OGT, O-GlcNAc transferase. B. Scheme ofHAS2 locus on chromosome
8 and possible mechanism of the natural antisense transcript HAS2-AS1 in HAS2 mRNA
stabilization.participating to different cell activities including proliferation, migra-
tion, and inﬂammation in normal tissues and in organ pathology. The
most important aspect of hyaluronan signaling is the size. In fact the
hyaluronan size has speciﬁc importance in this context, it was demon-
strated that hyaluronan with different sizes can induce different signal-
ing pathways. These aspects were initially described in CD44 signaling
pathway [48] and then in TLR4 and 2 [49,50]. The hyaluronan is there-
fore able to interact with various receptors as large molecule with sev-
eral million Daltons (high molecular weight — HMW) as well as low
molecular weight (LMW). The effects of these polymers with different
molecular weight are markedly different triggering different signaling
pathways including NF-κB and ERK phosphorylation [51]. The hypothe-
sis proposed so far is the capacity of HMW to cluster the receptors on
cell membrane, modulating in this way the receptor activity [49]. If
LMW hyaluronan interacts with the receptors on cell membrane it is
unable to gather the proteins on the cell membrane and the signaling
differs strongly from that induced by HMWon the same cells. Fragmen-
tation of hyaluronan is therefore a critical aspect in the hyaluronan
signaling capacity. Usually the hyaluronan catabolism is catalyzed by
hyaluronidases, which are hydrolases and include six enzymes in
mammals (Hyal-1, -2, -3, -4, P1 and PH20) [52]. Hyal-1 and -2 are
able to produce fragments with different sizes working sequentially,
Hyal-2 degrades hyaluronan in fragments of up 20 kDa whereas Hyal-1
reduced them to up 800 Da. Moreover, free radicals are also responsible
for hyaluronan fragmentation during tissue injuries [53,54]. The
hyaluronan fragments are usually internalized by the cells throughout
CD44 receptor, but in the presence of free radical production or in excess
of oligomers, as in inﬂammation or in certain tumors where the
hyaluronidase activity is high, hyaluronan fragments remain in the cell
microenvironment free to interact with hyaluronan receptors. It was
therefore critical the minimal size of hyaluronan able to trigger the cell
response. The active hyaluronan sizemay range from4 to6 disaccharides
units (4–6 mers), and they are able to induce NF-κB signaling and
metalloprotease production [55,56], whereas oligosaccharides with size
from4 to 16mers are able to induce inﬂammatory responses in dendritic
cells [50,57–59]. Considering the critical role of inﬂammation in cancer
microenvironment [60], the function of hyaluronan with high or low
molecular weight is obviously critical in cancer progression [61,62]. The
role of hyaluronan fragments in inﬂammation was described in several
cell and animal models [63,64], whereas the intact hyaluronan protects
tissue damage [65].
The biological effects of HMW and LMW are due to the different
activities of the receptor; for instance, HMW hyaluronan (N1000 kDa)
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Fig. 3. Schematic representation of the signaling cascade of hyaluronan receptors and their involvement in cell and tissue functions.
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disaccharides are strongly pro-angiogenic in human cell model [67],
all these cell behaviors are triggered by CD44 and RHAMM receptors.
3.1. CD44
Among the receptors involved in hyaluronan signaling, the CD44 is
the most common on cell membranes and it is present in almost all
human cells [68,69]. CD44 is a type I transmembrane protein existing
in at least 10 different splicing variants encoding for its extracellular do-
main and different grades of glycosylation [70]. CD44 is a glycoprotein
or a part-time proteoglycan and its sulfated glycosaminoglycan chains
(chondroitin or heparan sulfate) can interact with different growth fac-
tors aswell as cytokines and extracellularmatrix proteins as ﬁbronectin
[69]. Its role in this context is mainly due to its capacity to work
as docking agent forMMP9 or as growth factor reservoir. One of the spe-
ciﬁc function of CD44 is the capacity to bind and internalize HA. The
most common form in mammals is the standard form of CD44 with a
molecular mass of 85 kDa. The cytoplasmic domain is highly conserved
and could be phosphorylated to transduce the signal when the ligand
binds the extracellular domain. The CD44 signaling cascade is critical
for BMP-7 stimulation, involving SMAD1–4 phosphorylation before
their nuclear translocation, and all these signaling processes require a
hyaluronan binding on CD44 [71]. Besides the role of CD44 in cell adhe-
siveness, the phosphorylation of cytoplasmic CD44 domain is critical for
cell migration and inﬁltration, as demonstrated in melanoma model
[72], conﬁrming the pivotal role of the HA–CD44 interaction in cancer
cell migration. It is noteworthy that CD44 is highly expressed on cancer
cell membranes and its capacity to interact with cytoskeleton explains
its ability to promote cell motility. Moreover, CD44 in ﬁbroblasts is
responsible for cell migrations into the ﬁbrotic area contributing to
matrix alterations [73].
The signaling cascade triggered by CD44 includes PI3K/PDK1/Akt
activity as well as Ras phosphorylation cascade involving RAF1, MEK
and ERK1/2. It is demonstrated that the inhibition of ERK1/2 phosphor-
ylation abrogates the CD44 dependent motility during cell aging [74].
Ezrin,merlin and erbB1,2 are involved in CD44 cytoplasmic signaling
forming a complex with CD44 cytosolic domain with Hsp90 [62]. The
complexity of hyaluronan signaling through CD44, for example the
hyaluronan–CD44 interactions with leukemia-associated RhoGEF and
epidermal growth factor receptor promote Rho/Ras co-activation and
phospholipase C epsilon-Ca2+ signaling, was well described [75].
The role of hyaluronan on PDGF-BB receptor activity was reported,
showing that in the presence of hyaluronan CD44 is able to interact
with PDGF-BB receptor forming a complex on the cell membranepreventing PDGF-BB receptor activation. This effect is mediated by the
activity of a tyrosine phosphatase to the receptor [76]. The role of
CD44 hyaluronan complexes in keratinocytes from mice bearing an
antisense CD44 transgene was used to investigate its effect on cell
proliferation in response to speciﬁc skin stimuli [77].
During lung inﬂammation the critical role of CD44 in controlling the
inﬂammatory processwas demonstrated [78]. The CD44 is therefore in-
volved in the control of exaggerated inﬂammatory response downregu-
lating the signal of TLR4 [79]. The role of hyaluronan in inﬂammation
development is also demonstrated by the data reported in an animal
model where animal lungs were protected from LPS inﬂammation
damage by an aerosol pre-treatment with HMW hyaluronan [80].
CD44 signaling is critical in wound healing, where CD44 on ﬁbro-
blasts is critical for their migration in wounded area from perilesional
stroma [81]. It is noteworthy that CD44 per se is not able to induce cell
migration but only the interaction between HMW hyaluronan and
CD44 can induce cellmigration and promote thewoundhealing process
[82]. Moreover, the directionality of cell migration is strongly depen-
dent on CD44 expression and on hyaluronan gradient in extracellular
matrix environment [83].
3.2. RHAMM
RHAMM receptor takes its name from the acronym Receptor for
Hyaluronan Mediated Motility and it is also known as CD168. RHAMM
was described in tumor cell line [84,85] and in several cell types includ-
ing endothelial cells [86]. Several RHAMM isoforms are produced by
alternative splicing, and these transcript variants produce proteins
with a variable distribution such as on the cell surface, within the
cytoplasm, in the nucleus, or secreted extracellularly [87]. Intracellular
RHAMM can interact with actin ﬁlaments, the centrosome, microtu-
bules, and the mitotic spindle [88]. Moreover, it could be considered
a scaffold protein modulating the formation of extracellular signal-
regulated kinase 2 (ERK2), MEK1, and ERK1,2 complexes and control-
ling activation and targeting of ERK1,2 to speciﬁc substrates [89].
Hyaluronan–RHAMM interaction can trigger several cellular
signaling cascades probably working as a co-receptor for integral
membrane proteins [88]. These signaling molecules include Ras,
focal adhesion kinase (FAK), ERK1/2, protein kinase C (PKC), tyrosine
kinase pp60 (c-Src), NF-κB, and phosphatidylinositol kinase (PI3K)
[90,91].
RHAMM signaling seems to involve in some case Ras-oncogene
activity [92] but in other models the pathway seems different [93].
RHAMM defective cells showed a reduced ERK1/2 phosphorylation
and migration properties, indicating that signaling of RHAMM involves
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ﬂuenced CD44 localization on the plasmamembrane and signaling [94].
The interactions between hyaluronan and RHAMM play an impor-
tant role in tissue repair and inﬂammation [95]. In smooth muscle
cell cultures was demonstrated that the abrogation of hyaluronan-
mediated RHAMM signaling alters the cell migration and therefore
their capacity to heal tissue lesions. In macrophages the role of
RHAMM is also critical in the cell activation during the hyaluronan
incubation [95]. In ﬁbromatosis RHAMM is highly expressed and in
the ﬁbroblasts RHAMM stimulates their proliferation in vitro [96].
Conversely, the RHAMM abrogation in ﬁbroblasts reduced their healing
properties and migration capacity [94].
3.3. HARE
HARE takes its name from the acronym Hyaluronan Receptor for
Endocytosis and it is a 190 kDa polypeptide generated by the proteolytic
cleavage of stabilin 2 or FEEL2 [97]. This hyaluronan receptorwas initial-
ly isolated from sinusoidal endothelial cells in the liver, lymph nodes
and spleen [98], but its expression reﬂects the stage of development in
the organs [99]. HARE protein is described in the endothelial cells in
the liver, spleen and lymph nodes, it is also described in endothelial
cells from different tissues, including the eye, brain, kidney and heart.
The HARE structure is quite complex, including several hyaluronan
binding motifs (B(X7)B), fasciclin like binding domains and 18–20
EGF domains [100]. Interestingly, HARE can bind not only HA, but also
other chondroitin sulfate (CSA, C, D and E) with exception of heparin,
heparin sulfate and keratan sulfate [97,101]. HARE functions are related
to the hyaluronan endocytosis and this receptor is co-localized on cell
membrane of endothelial cells with clathrin, but then, during the endo-
cytosis process, HARE is not co-localized with internalized hyaluronan
during its way to lysosomes [102]. HARE is therefore not only speciﬁc
for hyaluronan only, but it is also able to recognize other GAGs. These
aspects reﬂect the role of HARE in the clearance of the GAGs from
circulation.
The interaction of HARE with hyaluronan of low molecular mass
(i.e., 80 kDa) is able to induce ERK1/2 activation whereas the uptake of
40–400-kDa, but not larger or smaller, hyaluronan stimulated NF-κB
activation [103]. However, it is still unclear whether hyaluronan
endocytosis is required for HARE-mediated cell signaling and whether
NF-κB and ERK activations are linked.
3.4. LYVE 1
LYVE 1 takes its name from the acronym Lymphatic Vessel Endothe-
lial hyaluronan receptor 1, also known as CRSBP1 that is for Cell Surface
Retention Sequence Binding Protein-1. It was described in human lym-
phatic system and then in mice [104,105]. LYVE 1 is a type I integral
membrane glycoprotein with a strong homology with CD44. Even if
the LYVE 1 expression is typically related to the lymphatic system,
LYVE1 receptors were also detected in sinusoidal endothelial cells in
the liver [106] and reticular cell of the lymph nodes [107].
Due to its abundant presence in lymphatic endothelial cells, LYVE 1
was used as speciﬁc marker to detect lymphatics [108], but it is also im-
portant in the prognostic assessment in head and neck squamous cell
carcinomas [109]. The internalization of LYVE 1 and its digestion in lyso-
somes is strongly dependent on the hyaluronan binding [110]. LYVE 1
works to absorb the hyaluronan from tissue to the lymph, regulating
therefore the tissue hydration and its biomechanical properties [105].
It is important to note that the expression of LYVE 1 was also reported
in macrophages [111]. Despite the critical role of the content control
of the amount of hyaluronan in the tissues, the abrogation of LYVE 1
did not generate abnormal animals, indicating that other receptors are
probably present in the lymphatics able to rescue the LYVE 1 abrogation
[112]. From these experiments it is evident that the role of LYVE 1 is
mainly related to the hyaluronan content control in tissues and it hasno role in the trafﬁcking of dendritic cells and other leukocytes in
lymph nodes, indicating that ICAM-1 and VCAM-1 are likely more
important in these processes [113].
Although the critical role of LYVE 1 in hyaluronan turnover, which
intracellular pathways are regulated by this receptor remains largely
unknown. LYVE 1 can form complex with ﬁbroblast growth factor-2
and this interaction could inhibit ﬁbroblast growth factor-2 induced
lymphangiogenesis [114]. CRSBP 1/LYVE 1 interacting with PDGFβR–
β-catenin complex, resulting in tyrosine phosphorylation of the com-
plex, dissociation of β-catenin and p120-catenin from VE-cadherin,
and internalization of VE-cadherin with the consequence of disruption
of VE-cadherin-mediated intercellular adhesion and opening of
intercellular junctions in lymphatic endothelial cell monolayers [115].
3.5. Toll like receptors
Toll like receptors (TLRs) are able to initiate the innate immune re-
sponse, which represents the ﬁrst defense against pathogens. The TLR
activation is a very rapid process, even if without the speciﬁcity of the
adaptive response [116,117]. TLR4 is a transmembrane receptor
able to recognize LPS molecules, whereas TLR2 is able to recognize
mycobacteria and gram positive bacteria [118]. After interaction with
hyaluronan oligosaccharides, the macrophages are able to activate che-
mokine genes, and this effect is strongly dependent onMyD88 presence
[49]. The abrogation of TLR2 and 4 as well as MyD88 abolished
completely the activation of chemokines in macrophages in in vitro
model [49]. Moreover, the treatment of dendritic cells with hyaluronan
oligosaccharides induced cell maturation throughout the phosphoryla-
tion cascade ofMAPK and nuclear translocation of NF-κB and eventually
the production of TNF-alpha. The role of hyaluronan fragments in innate
immune response is also demonstrated by theﬁndings in the skin trans-
plant rejection,where an increase of hyaluronan fragments is described,
suggesting a role of hyaluronan oligosaccharides in alloimmunity [119].
Moreover, the HMW hyaluronan is able to induce the expression of
IL-1R-associated kinase-M, which is a negative regulator of TLR
signaling. This phenomenon of deactivation is described in human
monocytes and the role of CD44 and TLR4 is experimentally
established [120]. The expression of MMP2 and IL8 is also stimulated
by hyaluronan fragments in part by the signaling of TLR4 [56]. HMW
hyaluronan is also able to inhibit the osteoclast differentiation by
TLR4 signaling, interfering with the signal triggered by macrophage
colony-stimulating factor (M-CSF) [121]. These effects of hyaluronan
on osteoclasts using TLR4 signaling highlight the possibility that be-
sides CD44, the hyaluronan interaction with receptor TLRs plays
a critical role not only in the innate immune response but also in
tissue metabolism. As reported for the gut, the interaction between
hyaluronan and TLRmay be considered a key element for tissue homeo-
stasis [122] triggering the synthesis of a class of proteins (defesins),
which have not only strong antibacterial properties but also exert a
strong regenerative stimulus for different cells [123]. The effects of
LMW hyaluronan are triggered by TLR4 and the signaling depends on
the activation of NF-κB pathway.
4. Conclusion and perspectives
An emerging body of literature highlights the role of hyaluronan in
several biological processes in different cell types and tissues, both in
normal condition and pathology. These observations suggest that HA,
besides its critical role as structural component of extracellular matrix,
has pivotal roles in tissue metabolism. Several receptors are described
in all tissueswith capacity to interact with hyaluronan and the signaling
pathways triggered by these receptors can control different genes in-
cluding chemokines and in the same time alters the cytoskeleton inter-
actions with cytoplasmic receptor domains. Moreover, the effects of
hyaluronan are strongly dependent on the molecular size, indicating
that polymer with a molecular weight of N1000 kDa can play roles
2457D. Vigetti et al. / Biochimica et Biophysica Acta 1840 (2014) 2452–2459inducing a clustering of receptor on cell membrane with an anti-
apoptotic activity. Fragments of hyaluronan with a mass of b200 kDa
can exert an opposite effect, with a strong pro-inﬂammatory stimulus
which was described in inﬂammatory cells and macrophages. It is an
intriguing aspect that the hyaluronan in epithelial cells can induce a sig-
naling inﬂuencing the synthesis of speciﬁc proteins involved not only in
the bacterial growth control but also in tissue regeneration and repair.
From this point of view the studies on hyaluronan signaling and
hyaluronan metabolism may represent a new target for an innovative
strategy in tissue repair and in the inﬂammation control.References
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